3M Company

NYSE:MMM 주식 리포트

시가총액: US$93.3b

3M 향후 성장

Future 기준 점검 2/6

3M (는) 각각 연간 12.2% 및 3.2% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 13.9% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 74% 로 예상됩니다.

핵심 정보

12.2%

이익 성장률

13.90%

EPS 성장률

Industrials 이익 성장10.1%
매출 성장률3.2%
향후 자기자본이익률74.02%
애널리스트 커버리지

Good

마지막 업데이트19 Aug 2026

최근 향후 성장 업데이트

Recent updates

내러티브 업데이트 • Aug 17

MMM: New Product Flywheel And Q2 Execution Will Support Future Re Rating

The analyst fair value estimate for 3M has been raised from $209 to $219 as analysts factor in stronger revenue growth assumptions, slightly higher profit margins, and updated P/E expectations following a series of post earnings price target increases across the Street. Analyst Commentary Recent research updates show a clear shift toward a more constructive view on 3M, with a cluster of higher price targets and some rating upgrades following the latest Q2 report.
내러티브 업데이트 • Aug 03

MMM: Q2 Execution And AI Ties Will Test PFAS Legal Overhang

The analyst price target for 3M has shifted higher in recent weeks, with the updated fair value estimate moving from about $171 to roughly $182, as analysts cite stronger Q2 earnings, improved organic growth and productivity, and a more confident multi year outlook for the company's product pipeline. Analyst Commentary Recent research on 3M shows a wide range of views on the stock, even as many analysts lift their price targets following the Q2 report and updated guidance.
Seeking Alpha • Jul 21

3M: The Turnaround Is Real, But Already Priced In

Summary 3M Company remains a Hold as valuation reached its fair value, even when taking into account the strong Q2 performance and guidance boost. 3M delivered 5.4% sales growth, 12% EPS growth in H1, and raised 2026 EPS guidance to $8.80–$8.95. Litigation liabilities and macro/geopolitical risks continue to weigh on 3M's risk-reward profile. AI/data center exposure and portfolio optimization offer long-term growth, but current risk-reward is unattractive. Read the full article on Seeking Alpha
내러티브 업데이트 • Jul 20

MMM: PFAS Lawsuits Will Continue To Cap Upside Despite Improving Demand

Analysts have adjusted their fair value estimate for 3M slightly lower to about $121.62. This reflects a modestly higher discount rate alongside marginally stronger assumptions for revenue growth, profit margins, and a lower future P/E, informed by recent price target changes that highlight both optimism around improving industrial demand and ongoing concerns about execution and legacy risks.
내러티브 업데이트 • Jul 06

MMM: Transformation And Legal Progress Will Support Future Re Rating

Analysts have trimmed their fair value estimate for 3M from $222.65 to $209.00. This reflects updated assumptions around discount rates, profit margins, and longer running concerns such as persistent PFAS liabilities and questions about the pace of the company's innovation recovery.
내러티브 업데이트 • Jun 22

MMM: Future Margin Execution Faces PFAS Legal Risks After Solventum Spin

Analysts have trimmed their price expectations for 3M, with the updated fair value estimate moving from about $175.03 to $170.97, as recent research has highlighted concerns around execution risks in reigniting growth and ongoing PFAS liabilities, even as margin assumptions improved slightly. Analyst Commentary Recent Street research on 3M points to a mixed setup, with analysts split between concerns around execution and liabilities and some recognition that management has pulled meaningful levers through the ongoing transformation and portfolio moves such as the Solventum spin.
내러티브 업데이트 • Jun 06

MMM: PFAS Lawsuit And Overhang Will Constrain Future Upside Potential

Analysts have adjusted their view on 3M, with the implied fair value price target moving from about $125.70 to around $127.90. This reflects updated assumptions on revenue growth, profit margins, and future P/E following the Solventum spin and mixed recent price target changes across the Street.
내러티브 업데이트 • May 23

MMM: Margin Execution And Cash Returns Will Support Future Re Rating

Analysts have trimmed their 3M price target by about $1, reflecting slightly lower fair value estimates even as updated models factor in a reduced discount rate, modestly higher revenue growth, a small uptick in projected profit margins, and a somewhat lower future P/E assumption. Analyst Commentary Recent Street research around 3M and its healthcare spin-off Solventum gives you a mixed but generally constructive picture, with attention on how the separation could reshape both companies' earnings profiles and valuation frameworks.
내러티브 업데이트 • May 03

MMM: Future Margin Execution And Buybacks Will Support Turnaround Prospects

Analysts have adjusted the 3M price target slightly lower to reflect a new fair value near $175, as recent target cuts from several firms and one smaller increase from Wells Fargo suggest a more cautious view on profit margins, while revenue growth assumptions and future P/E expectations remain steady to slightly higher. Analyst Commentary Recent Street research reflects a more mixed stance on 3M, with several firms trimming price targets and one lifting its target, all clustering around a fair value in the mid US$170s.
내러티브 업데이트 • Apr 18

MMM: Execution On Margin Efficiency And Buybacks Will Support Future Re Rating

Analysts have trimmed their 3M fair value estimate by about $2 to $223.59, reflecting slightly lower profit margin assumptions that are only partly balanced by a modestly higher revenue growth outlook and a marginally richer future P/E multiple. Analyst Commentary Recent Street research on 3M reflects a mix of cautious revisions and selective optimism, with several firms adjusting price targets both higher and lower in response to updated assumptions.
내러티브 업데이트 • Apr 04

MMM: Operational Discipline And Legal Resolution Will Support Future Re Rating

Analysts have reduced the updated price target on 3M by about $1 to $225.94. This reflects a combination of recent target cuts and increases across firms, along with slightly adjusted assumptions for discount rate, revenue growth, profit margin, and future P/E.
내러티브 업데이트 • Mar 21

MMM: Operational Progress And Legal Overhang Resolution Will Support Future Re Rating

The analyst price target for 3M has been adjusted by a few dollars, reflecting mixed but generally constructive updates from recent research. Some firms raised their targets by $2 to $5, while others trimmed theirs by $6 to $8, based on refreshed views of growth, profitability, and valuation assumptions.
내러티브 업데이트 • Mar 06

MMM: Digital And Legal Progress Will Support Future Re Rating

The analyst price target for 3M has edged higher by about $1.50, as analysts weighed mixed target moves from major firms alongside slightly updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E. Analyst Commentary Recent Street research on 3M has been mixed, with some firms trimming their price targets while others raised theirs.
내러티브 업데이트 • Feb 20

MMM: Digital Execution And Slightly Higher Fair Value Will Support Re Rating

The analyst price target for 3M has shifted slightly higher, with our fair value estimate moving from $223.00 to about $225.67 as analysts factor in updated growth and margin assumptions, along with mixed target revisions across major firms. Analyst Commentary Recent Street research on 3M shows a split view, with several bullish analysts lifting price targets and others trimming expectations or downgrading the stock.
내러티브 업데이트 • Feb 05

MMM: Turnaround Prospects Will Be Tested By PFAS Litigation And Mixed Street Expectations

The analyst price target on 3M has been revised slightly higher to about $177 from $174, as analysts adjust their models for small changes in fair value, discount rate, revenue growth, profit margin, and future P/E assumptions following a mix of recent target increases and cuts across major firms. Analyst Commentary Recent Street research on 3M has been mixed, with several firms adjusting their price targets in both directions and one major downgrade.
내러티브 업데이트 • Jan 22

MMM: New Digital Tools And Higher P E Multiple Will Support Re Rating

Analysts have nudged their valuation view on 3M higher, with the updated fair value estimate moving from $212 to $223 as they reassess the stock's longer term earnings power and apply a slightly richer future P/E multiple, despite mixed recent price target changes across the Street. Analyst Commentary Recent Street research on 3M has been mixed, with some firms trimming targets or ratings and others lifting their valuation marks.
내러티브 업데이트 • Jan 07

MMM: Reset Expectations And New Products Will Support Higher Margins

Analysts have raised their fair value estimate for 3M to $212 from $187, citing expectations for higher profit margins, a slightly lower discount rate, and supportive Street research that highlights Q3 execution, new product traction, and reset expectations across multiple firms. Analyst Commentary Recent Street research around 3M clusters around a more constructive setup following Q3, with several bullish analysts revisiting their models on the back of reset expectations, new product traction, and updated legal and macro assumptions.
내러티브 업데이트 • Dec 24

MMM: PFAS Litigation Will Ultimately Cap Upside Despite Turnaround Progress

Analysts have raised their price target on 3M, lifting fair value by about $12 per share to roughly $126 as they grow more confident in the company’s improving organic growth, margin expansion, and turnaround initiatives, despite ongoing PFAS litigation risks. Analyst Commentary Recent Street research reflects a more balanced, but still risk aware, view on 3M as estimates reset and execution on the turnaround improves.
내러티브 업데이트 • Dec 10

MMM: Turnaround Progress Will Face Ongoing PFAS Litigation And Portfolio Reshaping Risks

Our fair value estimate for 3M has been trimmed slightly to $174.25 from $174.94 as analysts balance higher price targets and improving expectations for new product driven growth and management's turnaround progress against persistent PFAS litigation risk. Analyst Commentary Street research remains divided on 3M, with recent notes highlighting improving execution and product driven growth, offset by continued concern around PFAS liabilities and mixed end market demand.
내러티브 업데이트 • Nov 26

MMM: Shares Will Balance Turnaround Progress With Litigation and Asset Sale Uncertainty

Analysts have marginally raised their fair value estimate for 3M to $174.94, citing improved organic growth, ongoing new product introductions, and increased profit margin expectations following recent quarterly results. Analyst Commentary Recent analyst research has revealed a shifting perspective on 3M, as several experts adjust their outlooks based on the company’s latest earnings performance and ongoing strategic initiatives.
내러티브 업데이트 • Nov 06

MMM: Shares Will Balance Turnaround Progress With Ongoing Litigation and Portfolio Changes

Analysts have raised their fair value estimate for 3M to $174.31 from $167.81. This change reflects improved organic growth prospects and progress on turnaround initiatives highlighted in recent research updates.
내러티브 업데이트 • Oct 22

Analysts Divided on 3M as Fair Value Rises Amid New Initiatives and Persistent Risks

3M's fair value estimate has increased by $5.00 to $167.81 as analysts cite modest operating outperformance and positive momentum from new product initiatives, despite some lingering concerns. Analyst Commentary Recent updates from Street research highlight diverging analyst sentiment regarding 3M's valuation trajectory and execution on strategic initiatives.
내러티브 업데이트 • Oct 08

New Product Launches And Efficiency Gains Will Boost Future Value

Narrative Update: 3M Analyst Price Target Revision Analysts have increased their price target for 3M to $162.81 from $161.63, citing improved full-year guidance prospects and renewed interest as a short-term buy idea. Analyst Commentary Recent commentary from Street research highlights both optimistic and cautious stances regarding 3M’s near-term prospects.
Seeking Alpha • Mar 11

3M: Multiple Expansion Amidst Turnaround Success

Summary 3M has shown signs of a turnaround with a doubling stock price since October 2023, but operational top line growth remains modest, justifying a "hold" rating. The company expects modest organic revenue growth of 2-3% in 2025, driven by innovations and new product launches, but analysts are less optimistic. Current valuation is high with a forward P/E ratio above the five-year median, limiting upside potential amid risks like trade disputes and economic slowdowns. Read the full article on Seeking Alpha
Seeking Alpha • Feb 07

3M: More Upside Ahead - But Wait For A Moderate Retracement

Summary MMM's reversal is already here, thanks to the SOLV divestiture bringing forth a more focused portfolio and healthier balance sheet. This is on top of the resolution of its legal headwinds, as management also pursues insurance recovery and $340M already completed. The management has driven new growth opportunities through its legacy businesses and new product launches as well, despite certain market softness. These reasons are likely why the market has upgraded MMM's valuations and the investors have defended the stock's uptrend support line thus far. With double digit capital appreciation prospects, we are reiterating our Buy rating here with one caveat. We shall further discuss. Read the full article on Seeking Alpha
Seeking Alpha • Jan 23

3M Is Structurally Shifting For Durable Growth

Summary 3M's focus on innovation and operational improvements under CEO Bill Brown may lead to significant top-line growth and margin expansion. Management is aiming to enhance supply chain efficiencies and increasing production launches while improving the firm's on-time, in-full deliveries. 3M has a substantial amount of inventory that may be worked down in the coming quarters, potentially acting as a tailwind for free cash flow generation in the coming years. Read the full article on Seeking Alpha
Seeking Alpha • Jan 06

Downgrading 3M Due To Persistent Litigation Risks And Stagnant Sales Growth

Summary I am downgrading 3M from hold to sell due to slow revenue growth, ongoing litigation risks, and inflated stock valuation despite recent gains. Revenue growth is expected to underpace inflation, driven by product line adjustments, declining European demand, and the healthcare spin-off. Despite settling some litigations, 3M faces significant pending lawsuits, posing substantial financial risks. Shares appear expensive when accounting for slow growth and litigation risks, with a fair value estimate of $86 per share, 34% below current trading. Read the full article on Seeking Alpha

이익 및 매출 성장 예측

NYSE:MMM - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수
12/31/202827,4285,0004,3855,9728
12/31/202726,4884,8094,5065,20814
12/31/202625,4013,9873,2795,06714
6/30/202625,1802,9973,9854,899N/A
3/31/202625,0242,7872,0602,959N/A
12/31/202524,9483,2501,3962,306N/A
9/30/202524,8253,4011,5882,541N/A
6/30/202524,6023,939-1,983-1,002N/A
3/31/202524,5134,420-69973N/A
12/31/202424,5754,0096381,819N/A
9/30/202424,5673,9157391,987N/A
6/30/202424,543164,2775,684N/A
3/31/202424,571-8,3594,6576,172N/A
12/31/202324,610-8,4025,0656,680N/A
9/30/202326,687-8,4954,8536,616N/A
6/30/202329,036-2,1094,4446,237N/A
3/31/202331,4555,1404,0555,855N/A
12/31/202226,1614,0133,8425,591N/A
9/30/202234,7626,5753,8755,674N/A
6/30/202235,0854,1504,3106,017N/A
3/31/202235,3335,5965,0606,777N/A
12/31/202135,3555,9215,8517,454N/A
9/30/202135,3265,9876,4957,964N/A
6/30/202134,7345,9837,0768,570N/A
3/31/202132,9605,7657,1098,588N/A
12/31/202032,1845,4496,6128,113N/A
9/30/202031,7125,0136,3197,936N/A
6/30/202031,3535,1665,8807,478N/A
3/31/202032,3484,987N/A7,235N/A
12/31/201932,1364,517N/A7,070N/A
9/30/201931,9704,948N/A6,990N/A
6/30/201932,1314,908N/A7,107N/A
3/31/201932,3505,638N/A7,344N/A
12/31/201832,7655,349N/A6,439N/A
9/30/201832,8104,525N/A6,041N/A
6/30/201832,8304,411N/A5,652N/A
3/31/201832,2504,137N/A5,395N/A
12/31/201731,6574,858N/A6,240N/A
9/30/201730,9965,490N/A6,589N/A
6/30/201730,5335,390N/A6,747N/A
3/31/201730,3855,098N/A6,390N/A
12/31/201630,1095,050N/A6,662N/A
9/30/201630,0784,933N/A6,791N/A
6/30/201630,0814,900N/A6,547N/A
3/31/201630,1054,909N/A6,600N/A
12/31/201530,2744,833N/A6,420N/A
9/30/201530,6954,974N/A6,265N/A

애널리스트 향후 성장 전망

수입 대 저축률: MMM 의 연간 예상 수익 증가율(12.2%)이 saving rate(3.7%)보다 높습니다.

수익 vs 시장: MMM 의 연간 수익(12.2%)이 US 시장(16.9%)보다 느리게 성장할 것으로 예상됩니다.

고성장 수익: MMM 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.

수익 대 시장: MMM 의 수익(연간 3.2%)이 US 시장(연간 12.9%)보다 느리게 성장할 것으로 예상됩니다.

고성장 매출: MMM 의 수익(연간 3.2%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: MMM의 자본 수익률은 3년 후 74%로 매우 높을 것으로 예상됩니다.

성장 기업 찾아보기

7D

1Y

7D

1Y

7D

1Y

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/08/19 20:33
종가2026/08/19 00:00
수익2026/06/30
연간 수익2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

3M Company는 30명의 분석가가 다루고 있습니다. 이 중 14명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
John EadeArgus Research Company
Robert CornellBarclays
Julian MitchellBarclays